Evidence map›Paper›PMID 34291308›Full record

ArticlePsychopharmacology2022

Cannabinoid receptor type 1 antagonists alter aspects of risk/reward decision making independent of toluene-mediated effects.

Kevin M Braunscheidel, Michael P Okas, Stan B Floresco, John J Woodward

Open access · greenAbstract read
In one paragraph

Article in Psychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Frontiers in neuroinformatics · 2024
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Kevin M BraunscheidelDepartment of Neuroscience, Medical University of South Carolina, MSC 861, 30 Courtenay Drive, Charleston, SC, 29425-5712, USA.
Michael P OkasDepartment of Neuroscience, Medical University of South Carolina, MSC 861, 30 Courtenay Drive, Charleston, SC, 29425-5712, USA.
Stan B FlorescoDepartment of Psychology and Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Colombia, V6T 1Z4, Canada.
John J WoodwardDepartment of Neuroscience, Medical University of South Carolina, MSC 861, 30 Courtenay Drive, Charleston, SC, 29425-5712, USA. woodward@musc.edu.
Medical University of South Carolina · USUniversity of British Columbia · CA

Funding

DRUG ABUSE TRAINING PROGRAMT32DA007288 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Christopher W Cowan, Rachel Penrod-Martin · 1991 to 2026
$11.8M
TRAINING IN ALCOHOL TREATMENT RESEARCHT32AA007474 · NIAAA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI John J. Woodward · 1987 to 2026
$8.5M
Neural Actions of TolueneR01DA013951 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI WOODWARD, JOHN J. · 2002 to 2023
$6.4M
Effect of Toluene on the Prefrontal-Amygdala Pathway and Risky BehaviorF31DA045485 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRAUNSCHEIDEL, KEVIN · 2018 to 2020
$105k
CIHR PJT-162444NIAAA NIH HHS T32 AA007474NIAAA NIH HHS T32AA007474NIDA NIH HHS F31 DA045485NIDA NIH HHS F31DA045485NIDA NIH HHS R01 DA013951NIDA NIH HHS R01DA013951NIDA NIH HHS T32 DA007288NIDA NIH HHS T32DA007288
6 · The paper itself

Abstract

Drugs of abuse including cannabis and inhalants impair risk/reward decision making. Cannabis use is often concurrent with inhalant intoxication; yet, preclinical studies investigating the role of endocannabinoids in inhalant misuse are limited. To address this gap in the literature, we used the well-validated probabilistic discounting task to assess risk/reward decision making in rodents following combinations of toluene vapor (a common inhalant) and manipulations of cannabinoid receptor type 1 (CB1R) signaling. As reported previously, acute exposure to toluene vapor disrupted behavioral flexibility during probabilistic discounting. Systemic administration of the CB1R inverse agonist AM281 did not prevent toluene-induced alterations in risky choices, but did independently reduce win-stay behavior, increase choice latency, and increase omissions. Toluene-induced deficits in probabilistic discounting are thought to involve impaired medial prefrontal cortex (mPFC) activity. As we previously reported that some of toluene's inhibitory effects on glutamatergic signaling in the mPFC are endocannabinoid-dependent, we tested the hypothesis that mPFC CB1R activity mediates toluene-induced deficits in discounting. However, bilateral injection of the CB1R inverse agonist AM251 prior to toluene vapor exposure had no effect on toluene-induced changes in risk behavior. In a final set of experiments, we injected the CB1R inverse agonist AM251 (5 and 50 ng), the CB1R agonist WIN55,212-2 (50 ng and 500 ng), or vehicle into the mPFC prior to testing. While mPFC CB1R stimulation did not affect any of the measures tested, the CB1R inverse agonist caused a dose-dependent reduction in win-stay behavior without altering any other measures. Together, these studies indicate that toluene-induced deficits in probabilistic discounting are largely distinct from CB1R-dependent effects that include decreased effectiveness of positive reinforcement (mPFC CB1Rs), decision making speed, and task engagement (non-mPFC CB1Rs).

Indexed as

Cannabinoid Receptor AntagonistsTolueneCannabinoid Receptor AgonistsDecision MakingEndocannabinoidsReceptor, Cannabinoid, CB1Receptors, CannabinoidRewardCannabinoid Receptor AgonistsCannabinoid Receptor AntagonistsEndocannabinoidsReceptor, Cannabinoid, CB1Receptors, CannabinoidTolueneAM 251AM 281EndocannabinoidGamblingInhalantPrelimbic cortexRatWIN 55,212–2

Identifiers

PMID34291308
PMCPMC9885490
OpenAlexW3183309707

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.